Prognostic Significance of Neutrophil–to–lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer

Ferroni, Patrizia; Roselli, Mario; Buonomo, Oreste Claudio; Spila, Antonella; Portarena, Ilaria; Laudisi, Anastasia; Valente, Maria Giovanna; Pirillo, Silvana; Fortunato, Lucio; Costarelli, Leopoldo; Cavaliere, F.

doi:10.21873/anticanres.12777

Cited by 18 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2) Patients Receiving Adjuvant Treatment Twenty-three studies reported data on NLR as a prognostic factor in patients with localized BC receiving adjuvant treatment . Most studies (n = 18; 78%) included patients with all BC molecular subtypes [32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48]. four included only patients withTNBC [49][50][51][52], and one work included patients with onlyhormone receptor-negative BC (independently of the HER2 status) [53].…”

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

“…Fifteen studies (65%) reported data on Asian populations [32,35,36,38,39,[42][43][44][46][47][48][49]51,53]. The adjuvant chemotherapy regimens were described only in six studies (anthracycline-and/or taxane-based regimens) [33,38,43,45,48,51]. (Table 3).…”

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

“…Studies including All BC Molecular Subtypes: seventeen studies analyzed the correlation between NLR and DFS after adjuvant chemotherapy [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47]. In the univariate analysis, NLR was correlated with DFS in 14/17 articles (82%) [34,35,[37][38][39][40][41][42][44][45][46]46,47].…”

Section: Results On Nlr and Dfsmentioning

confidence: 99%

See 2 more Smart Citations

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

Inflammatory blood markers (IBM), such as the neutrophil to lymphocyte ratio (NLR), have emerged as potential prognostic factors in various cancers, including breast cancer (BC), potentially allowing an easy, minimally invasive evaluation of a given cancer‘s prognosis and treatment outcome. We report here a systematic overview of the published data evaluating NLR as a prognostic factor or predictive factor for pathological complete response (PCR) and toxicity in early and advanced BC. A total of 45 articles were identified. NLR was found to be an independent prognostic factor for survival in most of the adjuvant treatment studies. However, no significant correlation was found between survival and NLR for early BC patients receiving neo-adjuvant chemotherapy (NACT) and advanced BC patients. Most studies failed to find a significant correlation between NLR and PCR after NACT. Finally, some data showed that IBM could be predictive of chemotherapy-related toxicity.

show abstract

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

Section: Results On Other Inflammatory Blood Markersmentioning

confidence: 99%

See 1 more Smart Citation

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Corbeau

Jacot

Guiu

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Several studies and a recent meta-analysis have confirmed and extend the prognostic role of NLR in breast cancer [113][114][115]. However, Ferroni et al [115] demonstrated that the NLR may represent a negative prognostic factor to define distant metastasis-free survival, especially in stage I breast cancer, but not for local recurrence. Following their suggestions, the NLR prognostic value should be regarded with caution, and additional studies are required to consolidate the clinical value of NLR.…”

Section: Neutrophilsmentioning

confidence: 95%

“…Following their suggestions, the NLR prognostic value should be regarded with caution, and additional studies are required to consolidate the clinical value of NLR. Nevertheless, in stage I patients the presence of a high NLR might raise the question as to whether they should be more aggressively managed [113][114][115]. Furthermore, a retrospective study was performed to investigate the role of NLR in breast cancer patients receiving neoadjuvant chemotherapy [116]: the pCR rate in patients with low pre-treatment NLR (NLR < 2.06) was higher than in those with higher NLR (NLR ≥ 2.06) (24.5 vs.14.3%, p < 0.05).…”

Section: Neutrophilsmentioning

confidence: 99%

The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas

et al. 2020

View full text Add to dashboard Cite

Heterogeneity in breast carcinomas can be appreciated at various levels, from morphology to molecular alterations, and there are well-known genotypic-phenotypic correlations. Clinical decision-making is strictly focused on the evaluation of tumor cells and is based on the assessment of hormone receptors and of the HER2 status, by means of a combination of immunohistochemical and in situ hybridization techniques. The tumor microenvironment (TME) also shows a multifaceted nature stemming from the different actors populating the intratumoral and the peritumoral stroma of breast carcinomas. Of note, we have now evidence that tumor-infiltrating lymphocytes (TILs) are clinically meaningful as their quantification in the intratumoral stroma strongly correlates with good prognosis, in particular in triple-negative and HER2-positive breast cancer patients. Nevertheless, TILs are just one of the many actors orchestrating the com-plexity of the TME, which is populated by immune and nonimmune cells (cancer-associated fibroblasts, cancer-associated adipocytes), as well as non-cellular components such as chemical inflammation mediators. In this review article we will overview the main features of the distinct cell compartments by discussing (i) the potential impact the TME may have on the prognostic stratification of breast cancers and (ii) the possible predictive value of some markers in the context of immunotherapy in light of the recent results of phase III studies in advanced and early triple-negative breast cancer patients.

show abstract

Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals

et al. 2019

View full text Add to dashboard Cite

Aims This study aimed to evaluate the prognostic effect of neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) for patients with breast cancer (BC). Methods A literature search was performed by searching medical databases. Basic characteristics and prognostic data were extracted from included studies. Primary outcomes, such as overall survival (OS) and disease‐free survival (DFS), were synthesized and compared. Subgroup analyses were performed according to pathology, geographical region, cut‐off value, and tumor progression. Results A total of 39 studies comprising 17079 BC patients were included in this meta‐analysis. Among them, 28 studies with 142 64 BC patients investigated predicting role of NLR for OS, showing elevated NLR were associated poor prognosis (hazard ratio [HR]: 1.78, 95% confidence interval [CI]: 1.49‐2.13, P < 0.001). Twenty‐seven studies containing 115 04 patients explored the role of NLR in predicting DFS, showing elevated NLR was associated with poor DFS with HR of 1.60 (95% CI: 1.42‐1.96, P < 0.001). Twelve studies explored the role of PLR in predicting OS, showing patients with higher PLR were associated with a significantly worse prognosis with a pooled HR of 1.32 (95% CI: 1.11‐1.57, P = 0.002). Eleven studies with 5013 patients shown patients with elevated PLR were associated shorter DFS (HR: 1.43, 95% CI: 1.09‐1.86, P = 0.009). Subgroup analyses shown a greater magnitude of association between NLR and OS in triple‐negative BC patients than in HER2‐positive ones. Conclusions Our study suggested that elevated NLR and PLR were associated with poor OS as well as high risk of recurrence for BC patients. Subgroup analyses confirmed the prognostic effect of NLR and PLR in HER2‐positive BC patients. As easily accessible parameters, NLR and PLR should be identified as useful biomarkers in the management of BC.

show abstract

Prognostic Significance of Neutrophil–to–lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer

Abstract: NLR might provide important information in risk stratification, especially in stage I BC patients in whom the presence of a high NLR might raise the question as to whether they should be more aggressively managed.

Cited by 18 publications

References 21 publications

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review

The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas

Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals

Contact Info

Product

Resources

About